News
All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.
Researchers found that at week 24, 81 and 16% of the treated and control wounds, respectively, were at least 50% healed from baseline.
HealthDay News — Women who have used the oral contraceptive desogestrel (75µg) for more than 5 continuous years have a small increased risk of intracranial meningioma, according to a study published ...
HealthDay News — Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI), according to a study published online June 17 in ...
The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for the treatment of high-risk, Bacillus Calmette-Guérin ...
Benlysta is supplied as a single-dose prefilled autoinjector or prefilled syringe containing 200mg/mL of belimumab for SC use. The prefilled syringe has not been studied in pediatric patients aged ...
Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.
HealthDay News — US drug overdose deaths (DODs) started declining in 2023, with a faster decline for opioid-related versus stimulant-related DOD rates, according to a study published online June 12 in ...
HealthDay News — Electroconvulsive therapy (ECT) shows a significant protective effect against suicide and overall mortality in people with depression, according to a review published online June 12 ...
HealthDay News — Hypertension is the most common chronic condition among adults aged 85 years and older, with prevalence higher among women than men, according to a report published in the June Health ...
ST-100 is a novel collagen mimetic peptide designed to repair damaged collagen in the eye and restore homeostatic cell signaling in the ocular epithelium.
The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results